Geron Corporation (0IV3.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Geron Corporation
Address
919 East Hillsdale Boulevard
Foster City, CA 94404
United States of America (the)
Phone
650 473 7700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
258
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Harout Semerjian | Chief Executive Officer, President & Director | 526,355 | 1970 |
| Ahmed ElNawawi | Executive Vice President & Chief Commercial Officer | 307,934 | 1981 |
| Timothy Williams | Executive Vice President, Chief Legal Officer & Corporate Secretary | 485,317 | 1977 |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | 810,552 | 1967 |
| Joseph Emile Eid | Executive Vice President of Research & Development and Chief Medical Officer | 1M | 1967 |
| Aron Feingold | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Shanthakumar Tyavanagimatt | Senior Vice President & Chief Technical Officer | 0 | N/A |
| Shannon Odam | Executive Vice President & Chief People Officer | 0 | 1975 |
| Dawn Schottlandt | Senior Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Bryan Ridgell | Senior Vice President of Portfolio & Project Management and Chief of Staff | 0 | N/A |
Description
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
